Skip to content
AnthropicAnthropic

Scaling enterprise AI: Fireside chat with Eli Lilly’s Diogo Rau and Dario Amodei

Dario Amodei, CEO and co-founder at Anthropic, sits down with Diogo Rau, Chief Information and Digital Officer at Eli Lilly and Company, to discuss building enterprise AI for regulated industries like life sciences. In his role at Lilly, Diogo is responsible for setting the pharmaceutical leader’s AI strategy, including how organizations use models like Claude to power clinical research and drug development. The two discuss Anthropic’s approach to building more steerable and reliable AI for enterprise deployments, our commitment to creating more skills for life sciences use cases, and the importance of building specialized models to power industry-specific solutions. Learn more about what Claude can do for life sciences: https://claude.com/solutions/life-sciences

Dario AmodeiguestDiogo Rauhost
Oct 19, 20255mWatch on YouTube ↗

At a glance

WHAT IT’S REALLY ABOUT

Why enterprise AI needs truth, domain skills, and ambition

  1. Dario Amodei argues enterprise AI should prioritize accuracy and reliability over consumer-style engagement incentives that can produce sycophantic, overly agreeable outputs.
  2. Anthropic differentiates by designing models to seek truth rather than validate user ideas, which is critical when decisions can cost millions and affect patient outcomes.
  3. The conversation highlights a strategy of creating specialized “Claudes” through fine-tuning and by wrapping models with domain data sources (e.g., financial indices; life sciences databases).
  4. Amodei advises life sciences leaders to plan for rapid model progress and prepare now for end-to-end workflow transformation rather than only optimizing isolated steps.
  5. Delaying adoption until models are “perfect” can add years of lag, slowing real-world benefits—especially in drug discovery and development timelines.

IDEAS WORTH REMEMBERING

5 ideas

Enterprise AI should be optimized for truth, not engagement.

Amodei contrasts consumer AI incentives (growth/engagement) with enterprise needs, warning that “sycophancy” can produce dangerously agreeable answers in high-stakes settings like drug R&D.

Sycophancy is not a nuisance—it’s a business and safety risk.

In life sciences, a model that reflexively praises a compound or plan could drive costly misallocation of resources; enterprises need models that challenge assumptions and surface uncertainty.

Domain capability improvements matter far more to enterprises than to general consumers.

He notes that moving from undergraduate- to graduate-level biochemistry knowledge may be invisible to most consumers, but materially valuable to organizations like Eli Lilly.

Specialized AI often requires both model improvements and context injection.

Anthropic’s “specialized Claudes” can involve fine-tuning the model and/or “wrapping” it with access to curated information sources, as illustrated by financial services integrations with indices and ratings.

Life sciences AI value depends on tight coupling to real scientific data ecosystems.

Amodei suggests a life sciences Claude should have relevant databases—proteins, compounds, assays—“at the model’s fingertips,” implying retrieval/integration is central to usefulness.

WORDS WORTH SAVING

5 quotes

I think it's more compatible with making the models smarter, making them better at a wide variety of economically valuable tasks, and it causes us to put a premium on accuracy and reliability.

— Dario Amodei

You really don't, you really don't want the model to say, "Oh, yeah, this drug compound's great." "You should spend millions of dollars to," you know. I just think this is ... You know, I think your idea's great. I think it's really promising. Like, you, you want truth.

— Dario Amodei

There is a temptation, and, and it's, it's ... I think it's hard to avoid starting this way, of, you know, what are the small things we can do with AI?

— Dario Amodei

Let's start preparing to do the whole thing end to end. Let's have faith in the pace of progress of the technology.

— Dario Amodei

Because if the models get good enough to do it end to end a year from now and only then you start deploying it, there'll be another two-year delay, and that's, you know, that's two years during which all the work that you're doing to benefit patients is not happening.

— Dario Amodei

Enterprise vs consumer AI incentivesModel sycophancy and truth-seeking behaviorAccuracy and reliability as product prioritiesSpecialized models (“skills” and specialized Claudes)Fine-tuning vs data/tool wrapping approachesLife sciences integration with protein/compound/assay databasesEnd-to-end workflow redesign vs incremental automation

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome